SNPMiner Trials by Shray Alag


SNPMiner Trials: Mutation Report


Report for Mutation C23S

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence

This project will evaluate the role of the 5-HT2CR:5-HT2AR balance in impulsive action and cue reactivity in cocaine-dependent subjects as compared to non-drug using controls.

NCT03921151 Cocaine Dependence Drug: Mirtazapine 15 MG (administered at Scan 1) and Placebo oral capsule (administered at Scan 2) Drug: Placebo oral capsule (administered at Scan 1) and Mirtazapine 15 MG (administered at Scan 2)
MeSH: Cocaine-Related Disorders

Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action.. fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose. --- Cys23Ser ---

Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity. --- Cys23Ser ---

Brain and behavioral responses to the 5-HT2AR blocking medication mirtazapine will be compared between subjects who have high and low functioning of the 5-HT2CR based on presence of a specific, functionally-relevant single nucleotide polymorphism (SNP) of the 5-HT2CR (Cys23Ser). --- Cys23Ser ---

The 5-HT2CR Cys23Ser SNP is thought to decrease the function of the protein and a preliminary observation indicates cocaine-dependent subjects carrying the CC genotype (Ser23 protein variant) display significantly higher cue reactivity. --- Cys23Ser ---

Primary Outcomes

Description: fMRI activation during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose

Measure: Interaction of the serotonin receptor (5-HTR) type-2C Cys23Ser single nucleotide polymorphism (SNP) and a 5-HT2AR antagonist on the functional circuitry underlying impulsive action.

Time: 1 day

Secondary Outcomes

Description: fMRI activation during Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Interaction of the 5-HT2CR Cys23Ser SNP and a 5-HT2AR antagonist on the functional circuitry underlying cue reactivity

Time: 1 day

Other Outcomes

Description: Impulsivity as measured by Go/NoGo task with placebo dose vs Mirtazapine dose

Measure: Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis impulsive action

Time: 1 day

Description: Cue reactivity as measured by Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Effective connectivity involved in the 5-HT2AR:5-HT2CR homeostasis cue reactivity

Time: 1 day

Description: fMRI activation with other 5-HT2CR SNPs during Attentional bias task with placebo dose vs Mirtazapine dose

Measure: Explore interactions between other 5-HT2CR SNPs and brain activation during attentional bias task after a 5- HT2AR antagonist

Time: 1 day

Description: fMRI activation with other 5-HT2CR SNPs during Go/NoGo (impulsivity) task with placebo dose vs Mirtazapine dose

Measure: Explore interactions between other 5-HT2CR SNPs and brain activation during Go/NoGo (impulsivity) task after a 5- HT2AR antagonist

Time: 1 day


HPO Nodes